The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
Vitamin D for the Prevention of Disease: An Endocrine
Society Clinical Practice Guideline
Marie B. Demay,1 Anastassios G. Pittas,2 Daniel D. Bikle,3 Dima L. Diab,4 Mairead E. Kiely,5
Marise Lazaretti-Castro,6 Paul Lips,7 Deborah M. Mitchell,8 M. Hassan Murad,9 Shelley Powers,10
Sudhaker D. Rao,11,12 Robert Scragg,13 John A. Tayek,14,15 Amy M. Valent,16 Judith M. E. Walsh,17
and Christopher R. McCartney18,19
1Department of Medicine, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
2Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA
3Departments of Medicine and Dermatology, University of California San Francisco, San Francisco VA Medical Center, San Francisco, CA
94158, USA
4Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati, OH 45267, USA
5Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences and INFANT Research Centre, University College
Cork, Cork, T12 Y337, Ireland
6Department of Internal Medicine, Division of Endocrinology, Universidade Federal de Sao Paulo, Sao Paulo 04220-00, Brazil
7Endocrine Section, Amsterdam University Medical Center, Internal Medicine, 1007 MB Amsterdam, Netherlands
8Pediatric Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
9Evidence-Based Practice Center, Mayo Clinic, Rochester, MN 55905, USA
10Bone Health and Osteoporosis Foundation, Los Gatos, CA 95032, USA
11Division of Endocrinology, Diabetes and Bone & Mineral Disorders, Henry Ford Health, Detroit, MI 48202, USA
12College of Human Medicine, Michigan State University, Lansing, MI 48824, USA
13School of Population Health, The University of Auckland, Auckland 1142, New Zealand
14Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA 90509, USA
15The Lundquist Institute, Torrance, CA 90502, USA
16Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR 97239, USA
17Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
18Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA
19Department of Medicine, West Virginia University, Morgantown, WV 26506, USA
Correspondence: Marie B. Demay, MD, Professor of Medicine, Department of Medicine, Endocrine Unit, Massachusetts General Hospital and Harvard Medical
School, 50 Blossom St, Thier 1113, Boston, MA 02114, USA. Email: mdemay@mgh.harvard.edu.
Co-Sponsoring Organizations: American Association of Clinical Endocrinology (AACE), European Society of Endocrinology (ESE), Pediatric Endocrine Society
(PES), American Society for Bone and Mineral Research (ASBMR), Vitamin D Workshop, American Society for Nutrition (ASN), Brazilian Society of
Endocrinology and Metabolism (SBEM), Society of General Internal Medicine (SGIM), Endocrine Society of India (ESI)
Abstract
Background: Numerous studies demonstrate associations between serum concentrations of 25-hydroxyvitamin D (25[OH]D) and a variety of
common disorders, including musculoskeletal, metabolic, cardiovascular, malignant, autoimmune, and infectious diseases. Although a causal link
between serum 25(OH)D concentrations and many disorders has not been clearly established, these associations have led to widespread
supplementation with vitamin D and increased laboratory testing for 25(OH)D in the general population. The benefit-risk ratio of this increase
in vitamin D use is not clear, and the optimal vitamin D intake and the role of testing for 25(OH)D for disease prevention remain uncertain.
Objective: To develop clinical guidelines for the use of vitamin D (cholecalciferol [vitamin D3] or ergocalciferol [vitamin D2]) to lower the risk of
disease in individuals without established indications for vitamin D treatment or 25(OH)D testing.
Methods: A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified
and prioritized 14 clinically relevant questions related to the use of vitamin D and 25(OH)D testing to lower the risk of disease. The panel prioritized
randomized placebo-controlled trials in general populations (without an established indication for vitamin D treatment or 25[OH]D testing),
evaluating the effects of empiric vitamin D administration throughout the lifespan, as well as in select conditions (pregnancy and
prediabetes). The panel defined “empiric supplementation” as vitamin D intake that (a) exceeds the Dietary Reference Intakes (DRI) and (b) is
implemented without testing for 25(OH)D. Systematic reviews queried electronic databases for publications related to these 14 clinical
questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the
certainty of evidence and guide recommendations. The approach incorporated perspectives from a patient representative and considered
patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. The
process to develop this clinical guideline did not use a risk assessment framework and was not designed to replace current DRI for vitamin D.
Received: 8 April 2024. Editorial Decision: 24 April 2024. Corrected and Typeset: 3 June 2024
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact
reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions
link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.
The Journal of Clinical Endocrinology & Metabolism, 2024, 00, 1–41
https://doi.org/10.1210/clinem/dgae290
Advance access publication 3 June 2024
Clinical Practice Guideline
Page 2
Results: The panel suggests empiric vitamin D supplementation for children and adolescents aged 1 to 18 years to prevent nutritional rickets
and because of its potential to lower the risk of respiratory tract infections; for those aged 75 years and older because of its potential to lower
the risk of mortality; for those who are pregnant because of its potential to lower the risk of preeclampsia, intra-uterine mortality, preterm
birth, small-for-gestational-age birth, and neonatal mortality; and for those with high-risk prediabetes because of its potential to reduce
progression to diabetes. Because the vitamin D doses in the included clinical trials varied considerably and many trial participants were
allowed to continue their own vitamin D–containing supplements, the optimal doses for empiric vitamin D supplementation remain
unclear for the populations considered. For nonpregnant people older than 50 years for whom vitamin D is indicated, the panel suggests
supplementation via daily administration of vitamin D, rather than intermittent use of high doses. The panel suggests against empiric
vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years. No clinical trial
evidence was found to support routine screening for 25(OH)D in the general population, nor in those with obesity or dark complexion,
and there was no clear evidence defining the optimal target level of 25(OH)D required for disease prevention in the populations
considered; thus, the panel suggests against routine 25(OH)D testing in all populations considered. The panel judged that, in most
situations, empiric vitamin D supplementation is inexpensive, feasible, acceptable to both healthy individuals and health care
professionals, and has no negative effect on health equity.
Conclusion: The panel suggests empiric vitamin D for those aged 1 to 18 years and adults over 75 years of age, those who are pregnant, and
those with high-risk prediabetes. Due to the scarcity of natural food sources rich in vitamin D, empiric supplementation can be achieved
through a combination of fortified foods and supplements that contain vitamin D. Based on the absence of supportive clinical trial
evidence, the panel suggests against routine 25(OH)D testing in the absence of established indications. These recommendations are not
meant to replace the current DRIs for vitamin D, nor do they apply to people with established indications for vitamin D treatment or
25(OH)D testing. Further research is needed to determine optimal 25(OH)D levels for specific health benefits.
Key Words: vitamin D, 25-hydroxyvitamin D, vitamin D deficiency, mortality, pregnancy, infection, prediabetes, clinical practice guidelines, systematic reviews
Introduction
The role of vitamin D in the regulation of skeletal and mineral
ion homeostasis is well established. Epidemiologic evidence
has shown consistent associations of low vitamin D status
with increased risk of a variety of common disorders, includ-
ing musculoskeletal, metabolic, cardiovascular, malignant,
autoimmune, and infectious diseases (1-3,). However, obser-
vational studies are prone to confounding and various forms
of bias, and a causal link between low vitamin D status, as as-
sessed by serum 25-hydroxyvitamin D (25[OH]D) levels, and
many disorders has not been clearly established. Nonetheless,
these associations have led to widespread supplementation
and increased laboratory testing for 25(OH)D levels in the
general population. In the United States, the prevalence of
supplemental vitamin D use of 1000 IU (25 μg) or more per
day increased from 0.3% in the 1999-2000 National Health
and Nutrition Examination Survey (NHANES) to 18.2% in
the 2013-2014 NHANES (4). The use of 25(OH)D testing
in clinical practice has also been increasing; however, the cost-
effectiveness of widespread testing has been questioned, espe-
cially given the uncertainty surrounding the optimal level of
25(OH)D required to prevent disease.
Vitamin D is not a true vitamin (defined as a nutrient that
cannot be endogenously synthesized), as intake is not required
in those who have adequate sun exposure. However, seasonal
variation in UV-B availability and decreased sun exposure as-
sociated with clothing and limited time outdoors has resulted
in the general population being increasingly reliant on oral in-
take of vitamin D in a few natural sources, foods fortified with
vitamin D, and supplements containing vitamin D. Whether
ingested or synthesized in the skin, vitamin D is converted to
25(OH)D in the liver (5). This process is not tightly regulated;
therefore, the 25(OH)D concentration most accurately reflects
vitamin D status. A second hydroxylation step (1-alpha) leads
to the formation of the active metabolite, 1,25-dihydroxyvita-
min D in many tissues. Circulating 1,25-dihydroxyvitamin D is
thought to derive primarily from renal 1-alpha hydroxylation
in the absence of pathologic conditions (6). Although loss of
function mutations in vitamin D hydroxylases are rare, genetic
variants and several pharmacologic agents may affect their ac-
tivity (7-10). Vitamin D metabolites are secreted with bile acids
and reabsorbed in the terminal ileum; therefore, terminal ileal
disease, as well as general malabsorption and having a short
gut (including from Roux-en-Y gastric bypass), can lead to
low levels of serum 25(OH)D. There are other conditions
that place individuals at risk for low 25(OH)D levels. For ex-
ample, vitamin D metabolites bound to vitamin D–binding
protein and albumin are lost in the urine of those with nephrot-
ic syndrome. In addition, vitamin D metabolites are inacti-
vated primarily by the 24-hydroxylase, which is induced by
high levels of 1,25-dihydroxyvitamin D as well as by fibroblast
growth factor-23, as seen in chronic kidney disease (11).
Importantly, these guidelines do not apply to individuals
with such underlying conditions that substantially alter vita-
min D physiology.
The actions of vitamin D metabolites are mediated by the
vitamin D receptor (VDR), which is expressed in most tissues.
The VDR has been shown to regulate cellular differentiation
and target gene expression in many cell types, including those
of the immune system. The best-established physiologic role of
the VDR is promoting intestinal calcium absorption, which is
critical for maintaining skeletal and mineral ion homeostasis
(12, 13). The skeletal effects of vitamin D are dependent on ad-
equate calcium intake. The effects of vitamin D on the immune
system are due to local activation of 25(OH)D to
1,25-dihydroxyvitamin D and induction of VDR expression
(14). Thus, the optimal level of 25(OH)D to prevent disease
likely depends on the clinical outcomes being evaluated.
Similarly, the required duration of exposure to vitamin D for
specific outcomes is expected to vary, depending on the under-
lying pathophysiology (eg, acute [infections] vs chronic
[cancer]).
In contrast to previous guidelines that broadly addressed
the evaluation, treatment, and prevention of vitamin D defi-
ciency, with an emphasis on the care of patients who are at
risk for deficiency (15), the goal of this Guideline
Development Panel was to establish clinical guidelines for
the use of vitamin D to lower the risk of disease in individuals
without established indications for vitamin D treatment or
25(OH)D testing. The panel recognized that there are numer-
ous important clinical questions regarding the use of vitamin
D and 25(OH)D testing in the general population; however,
due to limited resources, 14 of these clinical questions were
prioritized and 4 to 6 outcomes were addressed for each ques-
tion. Because patient-important clinical outcomes are
2 The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0
Page 3
expected to differ according to the target population, the pan-
el proposed specific outcomes for the pediatric population
(ages 1 to 18 years), and for ages 19 to 49 years, 50 to 74 years,
and 75 years and older. Established guidelines recommend
empiric vitamin D in the first year of life, specifically to prevent
nutritional rickets (16-18); thus, this demographic was not ad-
dressed. Other populations examined were pregnant individ-
uals and those with prediabetes, dark complexion, and
obesity. The panel also addressed whether daily supplementa-
tion with vitamin D should be recommended rather than inter-
mittent (nondaily), higher-dose vitamin D, and whether
supplementation should be limited to those with circulating
25(OH)D levels below a threshold.
Evidence from randomized controlled trials (RCTs) was pri-
oritized for the systematic reviews. Large (> 1000 participants)
longitudinal observational cohort studies were considered if
they included appropriate comparators (supplementation vs
no supplementation) and outcomes, but only when an insuffi-
cient number of RCTs was available. Trials where the interven-
tion was a vitamin D analog or metabolite other than vitamin
D2 or vitamin D3 were excluded because these compounds are
not globally available. Mendelian randomization studies were
excluded because they do not evaluate response to supplemen-
tation. The Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) methodology was
used to assess the certainty of evidence and inform recommen-
dations. The panel sought evidence relevant to all elements of
the Evidence-to-Decision (EtD) framework, which included
stakeholder values and preferences (including input from clin-
ical experts and a patient representative), costs and other re-
sources required, cost-effectiveness, acceptability, feasibility,
and impact on health equity. The panel did not identify robust
evidence pertinent to these EtD factors for most clinical
questions.
Limitations
In formulating this Guideline, several challenges were encoun-
tered that influenced the formulation of the final
recommendations.
1. Because those with lower baseline levels of 25(OH)D
are expected to benefit more from vitamin D supplemen-
tation than those with higher levels (19), a major limita-
tion in formulating recommendations was the paucity of
RCTs addressing the efficacy and safety of vitamin D
supplementation in populations with low baseline
25(OH)D levels. Average baseline levels of 25(OH)D
in many large trials were in a range that most would
consider adequate (eg, 31 ng/mL [78 nmol/L] in the
VITAL trial) (20). In such trials, a lack of effect of vita-
min D does not necessarily indicate that vitamin D does
not influence the relevant outcome, but rather that the
study populations had baseline levels of 25(OH)D that
were adequate for the desired outcome.
2. Unlike typical trials for pharmacologic agents, in which
control participants are not exposed to the intervention,
all participants in vitamin D trials were routinely ex-
posed to vitamin D through sun exposure and dietary
sources. In addition, many trials allowed participants
to remain on their current supplements that contained
vitamin D which often reflected the DRI (eg,
600-800 IU [15-20 μg] daily for adults). Such
circumstances may have biased trial results toward the
null hypothesis.
3. Most vitamin D trials did not include a specific 25(OH)
D level as an eligibility criterion, and no trials were de-
signed or powered to address the effect of vitamin D in
subgroups stratified by either baseline or achieved
25(OH)D levels. This prevented the panel from propos-
ing thresholds for 25(OH)D adequacy or providing tar-
get 25(OH)D levels for disease prevention, especially
since 25(OH)D thresholds are likely to vary by popula-
tion and outcome. Although many systematic reviews
include subgroup analyses according to the study aver-
age baseline 25(OH)D levels, such analyses are subject
to ecological fallacy in which inferences about individu-
als are based on aggregate group data. Therefore, the
commissioned systematic review informing this guide-
line does not include study subgroup analyses according
to average baseline 25(OH)D levels.
4. Many trials were considered to be of insufficient duration
to adequately assess the effect of the vitamin D interven-
tion on some outcomes, due to the long latency for the de-
velopment of chronic diseases such as cancer, diabetes,
cardiovascular disease (CVD) and osteoporosis.
5. Because the included trials used various doses and ad-
ministration schedules of vitamin D, specific dose rec-
ommendations for vitamin D could not be proposed
for specific populations. Instead, in the technical re-
marks, vitamin D doses used in the included trials are
summarized.
6. The trials that the panel considered were performed in
overall healthy populations at average risk for the out-
comes of interest; therefore, the recommendations are lim-
ited to generally healthy individuals without established
indications for vitamin D treatment or 25(OH)D testing.
7. In most trials, study participants were largely of European
ancestry or identified as non-Hispanic White, with very
few trials including large numbers of participants from
other races or ethnicities.
8. The panel developed clinical questions for different age
groups of adults (<50 years, 50 to 74 years, and 75 years
and older) to represent different stages of life. However,
the panel recognizes the somewhat arbitrary nature of
these categories and acknowledges that many trials in-
cluded populations that spanned these age categories.
As a result, it was challenging to directly apply study re-
sults to narrowly defined age groups.
9. Many trials in those aged older than 50 years combined
vitamin D with calcium, making it difficult to isolate the
effect of vitamin D from that of calcium. This is especially
relevant to outcomes related to skeletal health, for which
both vitamin D and calcium are considered essential.
10. Due to resource limitations, not all potential outcomes
of interest were addressed in all populations of interest.
The panel prioritized outcomes that they felt were most
relevant to the specific populations under consideration.
Thus, these clinical guidelines relate to the use of vitamin D to
lower the risk of disease in individuals without established indi-
cations for vitamin D treatment or 25(OH)D testing. The
Guideline Development Panel assumed that the Institute of
Medicine’s (IOM, now known as the National Academy of
Medicine) DRIs for vitamin D (21) represent a baseline standard
for all individuals. Importantly, the panel’s recommendations
The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0 3
Page 4
should not be extrapolated to those with underlying medical
conditions that are known to negatively impact vitamin D physi-
ology. For those living in countries where food fortification with
vitamin D is not standard or where dietary supplements are not
routinely used, interventions may be required to insure a baseline
intake consistent with the IOM DRIs.
List of Recommendations
Question 1. Should empiric vitamin D supplementation vs
no empiric vitamin D supplementation be used for chil-
dren and adolescents (ages 1 to 18 years)?
Recommendation 1
In children and adolescents aged 1 to 18 years, we
suggest empiric vitamin D supplementation to pre-
vent nutritional rickets and potentially lower the risk
of respiratory tract infections. (2 | ⊕⊕◯◯)
Technical remarks
• Empiric vitamin D may include daily intake of forti-
fied foods, vitamin formulations that contain vitamin
D, and/or daily intake of a vitamin D supplement (pill
or drops).
• In the clinical trials included in the systematic re-
view, with respect to respiratory tract infections
in children, vitamin D dosages ranged from 300
to 2000 IU (7.5 to 50 μg) daily equivalent. The esti-
mated weighted average was approximately
1200 IU (30 μg) per day.
Question 2. Should empiric vitamin D supplementation vs
no empiric vitamin D supplementation be used for non-
pregnant adults < 50 years of age?
Question 3. Should vitamin D supplementation vs no vita-
min D supplementation be used for nonpregnant adults
< 50 years of age only when 25(OH)D levels are below a
threshold?
Recommendation 2
In the general adult population younger than age
50 years, we suggest against empiric vitamin D sup-
plementation. (2 | ⊕◯◯◯)
Technical remark
• This recommendation relates to empiric vitamin D
supplementation that exceeds the DRIs established
by the IOM. Adults in this age group should follow
the Recommended Daily Allowance established by
the IOM (600 IU [15 μg] daily).
Recommendation 3
In the general adult population younger than age 50
years, we suggest against routine 25(OH)D testing.
(2 | ⊕◯◯◯)
Technical remarks
• In this population, 25(OH)D levels that provide
outcome-specific benefits have not been estab-
lished in clinical trials.
• The panel suggests against (a) routine screening
for a 25(OH)D level to guide decision-making (ie,
vitamin D vs no vitamin D) and (b) routine follow-
up testing for 25(OH)D level to guide vitamin D
dosing.
• This recommendation relates to generally healthy
adults who do not otherwise have established in-
dications for 25(OH)D testing (eg, hypocalcemia).
Question 4. Should empiric vitamin D supplementation vs
no empiric vitamin D supplementation be used for
adults aged 50 to 74 years?
Question 5. Should vitamin D supplementation vs no vita-
min D supplementation be used for adults aged 50 to 74
years only when 25(OH)D levels are below a threshold?
Recommendation 4
In the general population aged 50 to 74 years, we
suggest against routine vitamin D supplementation.
(2 | ⊕⊕⊕◯)
Technical remark
• This recommendation relates to empiric vitamin D
supplementation that exceeds the DRIs established
by the IOM. Adults in this age group should follow
the Recommended Daily Allowance established by
the IOM (600 IU [15 μg] daily for those aged 50 to
70 years; 800 IU [20 μg] daily for those older than
70 years).
Recommendation 5
In the general population aged 50 to 74 years, we sug-
gest against routine 25(OH)D testing. (2 | ⊕◯◯◯)
Technical remarks
• In this population, 25(OH)D levels that provide out-
come-specific benefits have not been established
in clinical trials.
4 The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0
Page 5
• The panel suggests against (a) routine screening for
a 25(OH)D level to guide decision-making (ie, vita-
min D vs no vitamin D) and (b) routine follow-up
testing for 25(OH)D level to guide vitamin D dosing.
• This recommendation relates to generally healthy
adults who do not otherwise have established in-
dications for 25(OH)D testing (eg, hypocalcemia).
Question 6. Should empiric vitamin D supplementation vs
no empiric vitamin D supplementation be used by adults
aged ≥ 75 years?
Question 7. Should vitamin D supplementation vs no vita-
min D supplementation be used by adults aged ≥ 75
years only when 25(OH)D levels are below a threshold?
Recommendation 6
In the general population aged 75 years and older, we
suggest empiric vitamin D supplementation because
of the potential to lower the risk of mortality.
(2 | ⊕⊕⊕◯)
Technical remarks
• Empiric vitamin D may include daily intake of forti-
fied foods, vitamin formulations that contain vita-
min D and/or daily intake of a vitamin D supplement.
• For empiric supplementation, daily, lower-dose
vitamin D is preferred over nondaily, higher doses.
• In the clinical trials included in the systematic re-
view that reported on the mortality outcome, vita-
min D dosage ranged from 400 to 3333 IU (10 to
83 μg) daily equivalent. The estimated weighted
average was approximately 900 IU (23 μg) daily.
Participants in many trials were allowed to remain
on their routine supplements, including up to 800
IU (20 μg) of vitamin D daily.
Recommendation 7
In the general population aged 75 years and older, we
suggest against routine testing for 25(OH)D levels. (2 |
⊕◯◯◯)
Technical remarks
• In this population, 25(OH)D thresholds that pro-
vide outcome-specific benefits have not been es-
tablished in clinical trials.
• The panel suggests against (a) routine screening for
a 25(OH)D level to guide decision-making (ie, vita-
min D vs no vitamin D) and (b) routine follow-up
testing for 25(OH)D level to guide vitamin D dosing.
• This recommendation relates to generally healthy
adults who do not otherwise have established in-
dications for 25(OH)D testing (eg, hypocalcemia).
Question 8. Should empiric vitamin D supplementation vs
no empiric vitamin D supplementation be used during
pregnancy?
Question 9. Should vitamin D supplementation vs no vita-
min D supplementation be used during pregnancy only
when 25(OH)D levels are below a threshold?
Recommendation 8
We suggest empiric vitamin D supplementation dur-
ing pregnancy, given its potential to lower risk of pre-
eclampsia, intra-uterine mortality, preterm birth,
small-for-gestational-age (SGA) birth, and neonatal
mortality. (2 | ⊕⊕◯◯)
Technical remarks
• This recommendation is based on evidence from
trials conducted in healthy individuals during
pregnancy.
• Empiric vitamin D may include daily intake of forti-
fied foods, prenatal vitamin formulations that con-
tain vitamin D, and/or a vitamin D supplement
(pills or drops).
• In the clinical trials included in the systematic re-
view, the vitamin D dosages ranged from 600 IU
to 5000 IU (15 to 125 μg) daily equivalent, usually
provided daily or weekly. The estimated weighted
average was approximately 2500 IU (63 μg) per
day.
Recommendation 9
During pregnancy, we suggest against routine 25(OH)
D testing. (2 | ⊕◯◯◯)
Technical remarks
• In this population, 25(OH)D levels that provide
pregnancy outcome-specific benefits have not
been established in clinical trials.
• The panel suggests against (a) routine screening
for a 25(OH)D level to guide decision-making (ie,
vitamin D vs no vitamin D) and (b) routine follow-
up testing for 25(OH)D level to guide vitamin D
dosing.
• This recommendation relates to generally healthy
pregnant individuals who do not otherwise have
established indications for 25(OH)D testing (eg,
hypocalcemia).
Question 10. Should empiric vitamin D supplementation vs
no empiric vitamin D supplementation be used for adults
with prediabetes (by glycemic criteria)?
The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0 5